scholarly journals EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects

2022 ◽  
Vol 146 ◽  
pp. 112532
Author(s):  
Mahshid Deldar Abad Paskeh ◽  
Atefeh Mehrabi ◽  
Mohammad Hossein Gholami ◽  
Amirhossein Zabolian ◽  
Ehsan Ranjbar ◽  
...  
2020 ◽  
Vol 48 (3) ◽  
pp. 933-943
Author(s):  
Glorianne Lazaro ◽  
Eleftherios Kostaras ◽  
Igor Vivanco

Aberrant activation of the PI3K pathway is one of the commonest oncogenic events in human cancer. AKT is a key mediator of PI3K oncogenic function, and thus has been intensely pursued as a therapeutic target. Multiple AKT inhibitors, broadly classified as either ATP-competitive or allosteric, are currently in various stages of clinical development. Herein, we review the evidence for AKT dependence in human tumours and focus on its therapeutic targeting by the two drug classes. We highlight the future prospects for the development and implementation of more effective context-specific AKT inhibitors aided by our increasing knowledge of both its regulation and some previously unrecognised non-canonical functions.


2011 ◽  
Vol 28 (2) ◽  
pp. 89-97 ◽  
Author(s):  
Mizuhiko Terasaki ◽  
Yasuo Sugita ◽  
Fumiko Arakawa ◽  
Yosuke Okada ◽  
Koichi Ohshima ◽  
...  

2018 ◽  
Vol 20 (suppl_6) ◽  
pp. vi74-vi74
Author(s):  
Choi-Fong Cho ◽  
Yarah Ghotmi ◽  
Colin Fadzan ◽  
Justin Wolfe ◽  
Sonja Bergmann ◽  
...  

Hematology ◽  
2011 ◽  
Vol 2011 (1) ◽  
pp. 538-542 ◽  
Author(s):  
Tomas Ganz ◽  
Elizabeta Nemeth

Abstract The review summarizes the current understanding of the role of hepcidin and ferroportin in normal iron homeostasis and its disorders. The various approaches to therapeutic targeting of hepcidin and ferroportin in iron-overload disorders (mainly hereditary hemochromatosis and β-thalassemia) and iron-restrictive anemias (anemias associated with infections, inflammatory disorders, and certain malignancies, anemia of chronic kidney diseases, and iron-refractory iron-deficiency anemia) are also discussed.


Diagnostics ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 670
Author(s):  
Valeria Simone ◽  
Daniela Rizzo ◽  
Alessandro Cocciolo ◽  
Anna Maria Caroleo ◽  
Andrea Carai ◽  
...  

Brain tumors in infants including those diagnosed in fetal age, newborns and under a year old represent less than 10% of pediatric nervous system tumors and present differently when compared with older children in terms of clinical traits, location and histology. The most frequent clinical finding is a macrocephaly but non-specific symptoms can also be associated. The prognosis is usually poor and depends on several factors. Surgery continues to be the main option in terms of therapeutic strategies whereas the role of chemotherapy is not yet well defined and radiotherapy is exceptionally undertaken. In view of this situation, a molecular characterization could assist in providing therapeutic options for these tumors. This review highlights the recent advances in the diagnosis and treatment of brain tumors in infants with a particular focus on the molecular landscape and future clinical applications.


2020 ◽  
Vol 21 (8) ◽  
pp. 2863 ◽  
Author(s):  
Maria L. Perepechaeva ◽  
Alevtina Y. Grishanova

Primary brain tumors, both malignant and benign, are diagnosed in adults at an incidence rate of approximately 23 people per 100 thousand. The role of AhR in carcinogenesis has been a subject of debate, given that this protein may act as either an oncogenic protein or a tumor suppressor in different cell types and contexts. Lately, there is growing evidence that aryl hydrocarbon receptor (AhR) plays an important part in the development of brain tumors. The role of AhR in brain tumors is complicated, depending on the type of tumor, on ligands that activate AhR, and other features of the pathological process. In this review, we summarize current knowledge about AhR in relation to brain tumors and provide an overview of AhR’s potential as a therapeutic target.


Author(s):  
Usman Beg ◽  
Brianna Michelle Snyder ◽  
Sarosh Irfan Madhani ◽  
Nima Hamidi ◽  
Varun Padmanaban ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document